The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome - PubMed (original) (raw)
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Minghan Wang. Nutr Metab (Lond). 2005.
Abstract
Glucocorticoids are stress hormones that modulate a large number of physiological actions involved in metabolic, inflammatory, cardiovascular and behavioral processes. The molecular mechanisms and the physiological effects of glucocorticoids have been extensively studied. However, the involvement of glucocorticoid action in the etiology of the Metabolic Syndrome has not been well appreciated. Recently, accumulating clinical evidence and animal genetics studies have attracted growing interest in the role of glucocorticoid action in obesity and insulin resistance. This review will discuss the metabolic effects in the context of glucocorticoid metabolism and establish the association of glucocorticoid action with the features of the Metabolic Syndrome, especially obesity and insulin resistance. Special discussions will be focused on corticosteroid-binding globulin and 11beta-hydroxysteroid dehydrogenase type 1, two proteins that mediate glucocorticoid action and have been implicated in the Metabolic Syndrome. Due to the complexities of the glucocorticoid biology and the Metabolic Syndrome and limited space, this review is only intended to provide a general link between the two areas with broad rather than in-depth discussions of clinical, pharmacological and genetic findings.
Figures
Figure 1
Glucocorticoid metabolism. The secretion of glucocorticoids by the adrenal gland is regulated by the HPA axis via secretion of ACTH. The main plasma cortisol (F) is protein bound with 4–5% free fraction. The plasma cortisone (E) is in the free unbound form. The equilibrium of cortisol and cortisone between the plasma and tissues are illustrated with the dotted bidirectional arrows. Tissue-specific GC metabolism are also depicted. GCs are metabolized primarily in liver and the metabolites are excreted in the urine. Only tissues relevant to the Metabolic Syndrome are shown. THE, tetrahydrocortisone; THF, tetrahydrocortisol.
Figure 2
The link between the metabolic effects of glucocorticoids and the features of the Metabolic Syndrome. The major effects in different tissues are summarized and the potential physiological links to the Metabolic Syndrome are shown.
Similar articles
- Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H, Flier JS. Masuzaki H, et al. Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):255-62. doi: 10.2174/1568008033340135. Curr Drug Targets Immune Endocr Metabol Disord. 2003. PMID: 14683456 Review. - 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?
Seckl JR. Seckl JR. Front Neuroendocrinol. 1997 Jan;18(1):49-99. doi: 10.1006/frne.1996.0143. Front Neuroendocrinol. 1997. PMID: 9000459 Review. - Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Atanasov AG, Odermatt A. Atanasov AG, et al. Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):125-40. doi: 10.2174/187153007780832082. Endocr Metab Immune Disord Drug Targets. 2007. PMID: 17584152 Review. - Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Oppermann U. Oppermann U. Endocr Metab Immune Disord Drug Targets. 2006 Sep;6(3):259-69. doi: 10.2174/187153006778250000. Endocr Metab Immune Disord Drug Targets. 2006. PMID: 17017977 Review. - 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM, Seckl JR. Morton NM, et al. Front Horm Res. 2008;36:146-164. doi: 10.1159/000115363. Front Horm Res. 2008. PMID: 18230901 Review.
Cited by
- Minireview: nuclear receptor coregulators of the p160 family: insights into inflammation and metabolism.
Rollins DA, Coppo M, Rogatsky I. Rollins DA, et al. Mol Endocrinol. 2015 Apr;29(4):502-17. doi: 10.1210/me.2015-1005. Epub 2015 Feb 3. Mol Endocrinol. 2015. PMID: 25647480 Free PMC article. Review. - Neuroendocrinological and Epigenetic Mechanisms Subserving Autonomic Imbalance and HPA Dysfunction in the Metabolic Syndrome.
Lemche E, Chaban OS, Lemche AV. Lemche E, et al. Front Neurosci. 2016 Apr 14;10:142. doi: 10.3389/fnins.2016.00142. eCollection 2016. Front Neurosci. 2016. PMID: 27147943 Free PMC article. Review. - Evaluation and optimization of differentiation conditions for human primary brown adipocytes.
Wang X, You L, Cui X, Li Y, Wang X, Xu P, Zhu L, Wen J, Pang L, Guo X, Ji C. Wang X, et al. Sci Rep. 2018 Mar 28;8(1):5304. doi: 10.1038/s41598-018-23700-z. Sci Rep. 2018. PMID: 29593245 Free PMC article. - Obesity-Related Hemodynamic Alterations in Patients with Cushing's Disease.
Jurek A, Krzesiński P, Uziębło-Życzkowska B, Witek P, Zieliński G, Wierzbowski R, Kazimierczak A, Banak M, Gielerak G. Jurek A, et al. J Clin Med. 2024 Mar 14;13(6):1658. doi: 10.3390/jcm13061658. J Clin Med. 2024. PMID: 38541884 Free PMC article. - Management factors affecting adrenal glucocorticoid activity of tourist camp elephants in Thailand and implications for elephant welfare.
Bansiddhi P, Brown JL, Khonmee J, Norkaew T, Nganvongpanit K, Punyapornwithaya V, Angkawanish T, Somgird C, Thitaram C. Bansiddhi P, et al. PLoS One. 2019 Oct 1;14(10):e0221537. doi: 10.1371/journal.pone.0221537. eCollection 2019. PLoS One. 2019. PMID: 31574099 Free PMC article.
References
- Reaven GM. Role of insulin resistance in human disease. Banting lecture. Diabetes. 1988;37:1595–1607. - PubMed
- Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care. 1991;14:195–202. - PubMed
- DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194. - PubMed
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation. 2002;106:3143–3421. - PubMed
- World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization. 1999. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials